Idiopathic inflammatory myopathies present profound diagnostic and therapeutic challenges across adult neurology. Among these complex disorders, inclusion body myositis remains notorious for its insidious progression and marked resistance to conventional immunosuppression. Historically, clinicians viewed this condition as an intractable degenerative process complicated by secondary inflammatory infiltrates. However, contemporary molecular insights have challenged this paradigm. Recent landmark investigations reveal that mitochondrial damage acts as a primary initiator of pathology, orchestrating early immune activation long before irreversible neuromuscular decline occurs.

Revisiting the Inclusion Body Myositis Spectrum

For several decades, neuromuscular specialists classified polymyositis with mitochondrial pathology as a separate clinical entity. Yet, comprehensive transcriptomic and proteomic analyses demonstrate significant molecular overlap between this condition and classical disease presentations. Consequently, experts now consider polymyositis with mitochondrial pathology to represent an early precursor within the unified inclusion body myositis disease spectrum. In this early phase, patients typically exhibit proximal muscle weakness without the hallmark rimmed vacuoles that define late-stage disease. Therefore, diagnostic delays frequently occur, preventing timely therapeutic stratification. Furthermore, early pathological biopsies reveal subtle organelle dysfunction alongside initial inflammatory cascades. By recognizing these shared biological signatures, clinicians can identify affected individuals much earlier in their clinical trajectory. Hence, viewing these conditions along a continuous spectrum transforms our understanding of disease progression. Furthermore, this paradigm shift emphasizes that structural mitochondrial degradation occurs well ahead of widespread myofiber degeneration.

Ultrastructural Evidence of Early Mitochondrial Disruption

Microscopic evaluation of patient muscle tissue confirms profound structural disintegration within the organelle network. Specifically, morphological staining shows an elevated frequency of cytochrome c oxidase-deficient fibers paired with robust succinate dehydrogenase reactivity. These classic ragged-red and ragged-blue fibers demonstrate a severe respiratory chain imbalance. In addition, transmission electron microscopy reveals markedly dysmorphic organelles characterized by disorganized, concentric, and swollen cristae. Interestingly, these ultrastructural anomalies appear equally pronounced in early precursor stages and fully established disease. Moreover, unbiased proteomic profiling demonstrates significant dysregulation of inner and outer mitochondrial membrane proteins. Because inner membrane integrity is essential for oxidative phosphorylation, this structural failure compromises cellular bioenergetics. Muscle fibers consequently experience metabolic crisis and heightened oxidative stress. Thus, structural breakdown of mitochondria is not merely a late consequence of tissue destruction. Instead, it represents an early, decisive driver of cellular pathology across the disease spectrum.

Mitochondrial DNA Depletion and Multiple Large-Scale Deletions

Beyond morphological damage, molecular analyses uncover severe genomic perturbations within the mitochondrial compartment. Quantitative polymerase chain reaction reveals a marked depletion of mitochondrial DNA copy numbers compared to healthy age-matched controls. Additionally, long-range sequencing identifies numerous large-scale deletions scattered throughout the mitochondrial genome. Notably, these genomic deletions are already prominent in precursor disease biopsies, mirroring findings observed in advanced cohorts. Single-molecule sequencing confirms that these deletions disrupt crucial genes encoding core components of the electron transport chain. Consequently, affected myocytes cannot sustain baseline adenosine triphosphate generation. In response to genomic instability, the mitochondrial quality control machinery attempts compensatory organelle proliferation. Nevertheless, this compensatory mechanism fails to restore energetic equilibrium because the replicated genomes harbor fatal deletions. Therefore, progressive genomic depletion locks muscle fibers into an energetic deficit. Furthermore, damaged mitochondrial fragments accumulate within the sarcoplasm, setting the stage for downstream immunological recognition.

Activation of the Innate cGAS-STING Inflammatory Axis

The release of damaged organelle contents establishes a direct molecular link between metabolic failure and immune activation. Because mitochondria originate from ancestral prokaryotes, displaced mitochondrial DNA functions as a potent damage-associated molecular pattern. When inner and outer membranes rupture, mitochondrial DNA leaks into the cytosol and systemic circulation. Accordingly, researchers detected significantly elevated levels of cell-free mitochondrial DNA in patient sera. Inside the muscle fiber, cytosolic DNA sensors, particularly cyclic GMP-AMP synthase, rapidly detect these unshielded double-stranded fragments. Upon binding DNA, this enzyme activates the stimulator of interferon genes pathway. Consequently, this signaling cascade triggers robust transcription of type I interferons and pro-inflammatory chemokines. Thus, sterile mitochondrial breakdown directly ignites an innate immune response before cytotoxic cells invade the tissue. In this manner, innate DNA sensing establishes an inflammatory microenvironment that subsequently recruits pathogenic lymphocytes.

Temporal Precedence Over Cytotoxic T-Cell Infiltration

Traditional diagnostic criteria for advanced myopathy emphasize extensive endomysial inflammation, especially invasion by clonal cytotoxic T cells. In particular, late-stage disease features terminally differentiated killer cell lectin-like receptor G1-positive CD8+ T cells that resist apoptosis. However, current chronological analysis reveals that mitochondrial damage emerges well before this cytotoxic invasion. In precursor biopsies, profound organelle abnormalities occur alongside interferon signaling, while aggressive T-cell clones remain largely absent. Therefore, cellular immune infiltration represents a secondary amplification loop rather than the initial inciting event. Chronic leakage of mitochondrial components continuously primes local antigen-presenting cells and vascular endothelium. Subsequently, persistent chemokine gradients attract specialized cytotoxic lymphocytes into the endomysium. This temporal hierarchy explains why therapies targeting mature lymphocytes fail to halt disease progression in late stages. Because the underlying mitochondrial driver remains unaddressed, ongoing cellular damage continually fuels chronic inflammatory cascades.

Therapeutic Repercussions and Future Clinical Directions

These mechanistic insights provide a compelling rationale for transforming contemporary treatment algorithms. Historically, clinicians administered high-dose corticosteroids and conventional immunosuppressants with negligible clinical efficacy. Given that mitochondrial rupture initiates the inflammatory cycle, immunomodulatory drugs alone cannot restore neuromuscular function. Instead, future therapeutic strategies must combine targeted innate immune inhibition with mitochondrial preservation. Specifically, small-molecule inhibitors targeting the cGAS-STING axis could prevent interferon-mediated tissue injury. Furthermore, enhancing mitochondrial quality control through pharmacological stimulation of mitophagy may clear damaged organelles before membrane leakage occurs. Clinical trials must also explore antioxidants targeted to the mitochondrial matrix to protect organelle DNA from oxidative destruction. Most importantly, clinicians must prioritize early diagnostic identification during the precursor phase. Intervening before irreversible muscle atrophy and clonal T-cell expansion take place offers the greatest hope for preserving physical independence in affected patients.

Frequently Asked Questions

How does polymyositis with mitochondrial pathology relate to inclusion body myositis?

Polymyositis with mitochondrial pathology represents an early precursor stage within the inclusion body myositis disease spectrum. Patients exhibit characteristic respiratory chain defects and mitochondrial DNA deletions before developing classical rimmed vacuoles or endomysial cytotoxic T-cell infiltrates, enabling earlier clinical recognition and potential intervention.

How does mitochondrial DNA leakage trigger inflammatory responses in muscle tissue?

When damaged mitochondria rupture, they release mitochondrial DNA into the sarcoplasm and circulation. Because this DNA resembles bacterial genetic material, the cytosolic cGAS sensor detects it and activates the STING pathway. This process stimulates type I interferon secretion, producing sterile inflammation that recruits immune cells.

Why do conventional immunosuppressive therapies fail in inclusion body myositis?

Standard immunosuppressive therapies fail because they target downstream adaptive immune responses, such as mature T cells, rather than upstream triggers. The underlying driving pathology involves severe mitochondrial membrane disruption, genomic deletions, and chronic innate immune activation via cGAS-STING, which standard immunosuppressive regimens do not correct.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Kleefeld F et al. Mitochondrial damage is associated with an early immune response in inclusion body myositis. Brain. 2025 Sep 03. doi: 10.1093/brain/awaf118. PMID: 40193586.
2. Zhang H, et al. Mitochondrial defects in sporadic inclusion body myositis—causes and consequences. Front Aging Neurosci. 2024;16:1396122. doi: 10.3389/fnagi.2024.1396122.
3. Rygiel KA, Grady JP, Turnbull DM. Sporadic inclusion body myositis: an acquired mitochondrial disease with extras. Int J Mol Sci. 2019;20(2):325. doi: 10.3390/ijms20020325.